A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease.
GV1001, a 16-amino acid peptide spun out of human telomerase reverse transcriptase, just made a comeback in Alzheimer’s research. This isn’t theory. In a mouse model packed with Alzheimer’s traits, the peptide slashed amyloid plaque buildup and reversed synaptic loss. Even memory deficits saw a turnaround, all thanks to a boost in microglial activity.
Exp Mol Med
by Lee Y, Nam H, Lee JW et al.
“A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease. Lee Y(#)(1), Nam H(#)(1), Lee JW(1), Ko YJ(2), Kim EJ(3), Ha S(1), Kim N(1), Koo JW(3), Son T(4), Kim S(5), Yu SW(6). Author information: (1)Department of Brain Sciences, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea. (2)Department of Physiology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. (3)Emotion, Cognitive & Behavior Research Group, Korea Brain Research Institute (KBRI), Daegu, Republic of Korea. (4)Korea Brain Bank, Korea Brain Research Institute (KBRI), Daegu, Republic of Korea. taekwon@kbri.re.kr. (5)Teloid Inc., Los Angeles, CA, USA. chiron@gemvax.com. (6)Department of Brain Sciences, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea. yusw@dgist.ac.kr. (#)Contributed equally GV1001 is a peptide consisting of 16 amino acids derived from the catalytic subunit of human telomerase reverse transcriptase. A recent phase II clinical trial in patients with Alzheimer disease (AD) showed that GV1001 effectively improved memory impairment with proven safety, leading to larger clinical trials. However, the mechanisms underlying therapeutic effects of GV1001 on AD remain elusive. Here, we report that GV1001 reduces amyloid plaque burden and rescues synaptic loss and memory deficits in 5xFAD mice by increasing microglial migration toward large amyloid plaques and amyloid β degradation. Single-cell RNA-sequencing revealed that GV1001 promoted the migratory and phagocytic phenotypes by modulating disease-associated microglial profiles. At the molecular level, through virtual target screening and docking simulation combined with peptide pulldown, we identified that bradykinin receptor 1 is the binding target of GV1001. Furthermore, we revealed that GV1001 facilitated microglial migration and amyloid β phagocytosis in an mTORC2-dependent manner. Collectively, our work demonstrates the amyloidolytic effects and the relevant in-depth signaling mechanism of GV1001 in microglia, suggesting GV1001 as a promising disease-modifying therapeutic agent for AD. © 2026. The Author(s). Conflict of interest statement: Competing interests: S.K. is an employer of GemVax & Kael Co., Ltd and holds equity in the company. All other authors declare no competing interests.”
Key takeaway: GV1001 doesn’t just float around. It commands microglia—the brain’s cleanup crew—to migrate toward big amyloid plaques and break down amyloid beta. Here’s how the study breaks it down:
Single-cell RNA sequencing showed GV1001 shifted microglia into a supercharged, migratory, and phagocytic (think: eating up plaque) mode.
The molecular target? Bradykinin receptor 1. Virtual screening, docking, and peptide pulldown pointed right at it.
mTORC2 signaling is involved. That’s the pathway driving microglial migration and amyloid beta phagocytosis.
Why does this matter for peptide researchers? GV1001 isn’t just another peptide with a vague “potential.” The signaling path is mapped, mechanisms are transparent, and effects are clear in a high-standard animal model. If you’re tracking research peptides for neurodegeneration, this is a model worth following.
A phase II clinical trial already showed GV1001 can improve memory impairment in humans, with a clean safety profile. That’s why bigger trials are rolling out. But in the lab, the peptide’s ability to modulate microglia through specific receptors and pathways sets a new bar for Alzheimer’s peptide research.
For more on the latest research peptides and their mechanisms, check the peptide research index. If you’re sourcing or comparing options, browse the vendor directory.
Alzheimer’s research just got a concrete, peptide-driven signal boost.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.